PL1611144T3 - Pochodne kwasu 2-(8,9-diokso-2,6-diazabicyklo(5.2.0)non-1(7)-en-2-ylo)alkilofosfonowego i ich zastosowanie jako antagonistów receptora N-metylo-D-asparaginianu (NMDA) - Google Patents

Pochodne kwasu 2-(8,9-diokso-2,6-diazabicyklo(5.2.0)non-1(7)-en-2-ylo)alkilofosfonowego i ich zastosowanie jako antagonistów receptora N-metylo-D-asparaginianu (NMDA)

Info

Publication number: PL1611144T3
Authority: PL; Poland
Prior art keywords: recetor; nmda; dioxo; diazabicyclo; aspartate
Prior art date: 2003-04-09

Application number

PL04759168T

Other languages

English (en)

Inventor

Reinhardt Bernhard Baudy

John Anthony Butera

Original Assignee

Wyeth Llc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-04-09

Filing date

2004-04-07

Publication date

2011-03-31

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33299828&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL1611144(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2004-04-07 Application filed by Wyeth Llc filed Critical Wyeth Llc

2011-03-31 Publication of PL1611144T3 publication Critical patent/PL1611144T3/pl

Links

HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 title 2
-1 alkyl phosphonic acid Chemical compound 0.000 title 1
239000005557 antagonist Substances 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A61P25/12—Antiepileptics; Anticonvulsants for grand-mal
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Life Sciences & Earth Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
General Chemical & Material Sciences (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Pain & Pain Management (AREA)
Diabetes (AREA)
Psychiatry (AREA)
Addiction (AREA)
Hematology (AREA)
Emergency Medicine (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Endocrinology (AREA)
Orthopedic Medicine & Surgery (AREA)
Ophthalmology & Optometry (AREA)
Obesity (AREA)
Biochemistry (AREA)
Rheumatology (AREA)
Psychology (AREA)
Molecular Biology (AREA)
Physical Education & Sports Medicine (AREA)
Hospice & Palliative Care (AREA)
Pulmonology (AREA)
Vascular Medicine (AREA)
Urology & Nephrology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

PL04759168T 2003-04-09 2004-04-07 Pochodne kwasu 2-(8,9-diokso-2,6-diazabicyklo(5.2.0)non-1(7)-en-2-ylo)alkilofosfonowego i ich zastosowanie jako antagonistów receptora N-metylo-D-asparaginianu (NMDA) PL1611144T3 (pl)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US46149003P	2003-04-09	2003-04-09
EP04759168A EP1611144B1 (en)	2003-04-09	2004-04-07	Derivatives of 2-(8,9-dioxo-2,6-diazabicyclo(5.2.0)non-1(7)-en-2-yl)alkyl phosphonic acid and their use as n-methyl-d-aspartate (nmda) recetor antagonists
PCT/US2004/010596 WO2004092189A1 (en)	2003-04-09	2004-04-07	Derivatives of 2-(8,9-dioxo-2,6-diazabicyclo(5.2.0)non-1(7)-en-2-yl)alkyl phosphonic acid and their use as n-methyl-d-aspartate (nmda) recetor antagonists

Publications (1)

Publication Number	Publication Date
PL1611144T3 true PL1611144T3 (pl)	2011-03-31

Family

ID=33299828

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL04759168T PL1611144T3 (pl)	2003-04-09	2004-04-07	Pochodne kwasu 2-(8,9-diokso-2,6-diazabicyklo(5.2.0)non-1(7)-en-2-ylo)alkilofosfonowego i ich zastosowanie jako antagonistów receptora N-metylo-D-asparaginianu (NMDA)

Country Status (19)

Country	Link
US (2)	US7253153B2 (pl)
EP (1)	EP1611144B1 (pl)
JP (1)	JP4621659B2 (pl)
CN (1)	CN1863810B (pl)
AR (1)	AR044013A1 (pl)
AT (1)	ATE481103T1 (pl)
AU (1)	AU2004230895B2 (pl)
BR (1)	BRPI0409255A (pl)
CA (1)	CA2521313A1 (pl)
CL (1)	CL2004000769A1 (pl)
CY (1)	CY1110863T1 (pl)
DE (1)	DE602004029146D1 (pl)
DK (1)	DK1611144T3 (pl)
ES (1)	ES2350449T3 (pl)
MX (1)	MXPA05010760A (pl)
PL (1)	PL1611144T3 (pl)
PT (1)	PT1611144E (pl)
TW (1)	TWI349674B (pl)
WO (1)	WO2004092189A1 (pl)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7687080B2 (en) *	2002-11-25	2010-03-30	Taraxos Inc.	Treatment of neuropathy
US7732162B2 (en)	2003-05-05	2010-06-08	Probiodrug Ag	Inhibitors of glutaminyl cyclase for treating neurodegenerative diseases
GT200400213A (es) *	2003-10-22	2007-09-05		Metodos para la preparacion del acido {2-[(8,9)-dioxo-2,6-diaza-biciclo[5.2.0]-non-1(7)-en-2-il]etil} fosfonico y esteres del mismo
US7268123B2 (en) *	2004-10-08	2007-09-11	Wyeth	Derivatives of [2-(8,9-dioxo-2,6-diazabicyclo[5.2.0]non-1(7)-en-2-yl)alkyl]phosphonic acid and methods of making them
US8278345B2 (en)	2006-11-09	2012-10-02	Probiodrug Ag	Inhibitors of glutaminyl cyclase
JP5523107B2 (ja)	2006-11-30	2014-06-18	プロビオドルグエージー	グルタミニルシクラーゼの新規阻害剤
EP2481408A3 (en)	2007-03-01	2013-01-09	Probiodrug AG	New use of glutaminyl cyclase inhibitors
WO2008128985A1 (en)	2007-04-18	2008-10-30	Probiodrug Ag	Thiourea derivatives as glutaminyl cyclase inhibitors
MX2010002191A (es) *	2007-08-27	2010-03-17	Wyeth Llc	Composiciones y metodos que emplean antagonistas nmda para lograr un efecto anestesico limitado.
BRPI0819696B1 (pt)	2007-11-29	2018-10-23	Actelion Pharmaceuticals Ltd	compostos de derivados de 2-fenil-pirimidina, composição farmacêutica e uso de um composto
AR071652A1 (es)	2008-04-11	2010-07-07	Actelion Pharmaceuticals Ltd	Derivados 2- fenil-piridina substituidos
AR071653A1 (es)	2008-04-11	2010-07-07	Actelion Pharmaceuticals Ltd	Derivados 2-fenil-4-ciclopropil-pirimidina
WO2010036937A1 (en) *	2008-09-27	2010-04-01	Taraxos Inc.	Topical formulations for treatment of neuropathy
WO2010116328A2 (en)	2009-04-08	2010-10-14	Actelion Pharmaceuticals Ltd	6-(3-aza-bicyclo[3.1.0]hex-3-yl)-2-phenyl-pyrimidines
MX2012002993A (es)	2009-09-11	2012-04-19	Probiodrug Ag	Derivados heterociclicos como inhibidores de ciclasa glutaminilo.
JP6026284B2 (ja)	2010-03-03	2016-11-16	プロビオドルグエージー	グルタミニルシクラーゼの阻害剤
US8269019B2 (en)	2010-03-10	2012-09-18	Probiodrug Ag	Inhibitors
WO2011131748A2 (en)	2010-04-21	2011-10-27	Probiodrug Ag	Novel inhibitors
ES2570167T3 (es)	2011-03-16	2016-05-17	Probiodrug Ag	Derivados de benzimidazol como inhibidores de glutaminil ciclasa
US9359376B2 (en)	2011-04-08	2016-06-07	Sphaera Pharma Pte. Ltd	Substituted methylformyl reagents and method of using same to modify physicochemical and/or pharmacokinetic properties of compounds
HUE057772T2 (hu)	2016-09-22	2022-06-28	Idorsia Pharmaceuticals Ltd	Kristályos formák
US11179390B2 (en)	2017-03-15	2021-11-23	Idorsia Pharmaceuticals Ltd	Subcutaneous administration of a P2Y12 receptor antagonist
PL3461819T3 (pl)	2017-09-29	2020-11-30	Probiodrug Ag	Inhibitory cyklazy glutaminylowej
US10902020B2 (en) *	2018-06-08	2021-01-26	International Business Machines Corporation	Multiple cache processing of streaming data

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5624898A (en) *	1989-12-05	1997-04-29	Ramsey Foundation	Method for administering neurologic agents to the brain
US5168103A (en) *	1991-01-22	1992-12-01	American Home Products Corporation	[[2-(amino-3,4-dioxo-1-cyclobuten-1-yl) amino]alkyl]-acid derivatives
US5124319A (en) *	1991-10-11	1992-06-23	American Home Products Corporation	Benzimidazole phosphono-amino acids
DK124393D0 (da)	1993-11-03	1993-11-03	Lundbeck & Co As H	Compounds
TW427904B (en)	1995-12-07	2001-04-01	American Home Prod	Neuroprotective agents
UA52698C2 (uk)	1996-10-04	2003-01-15	Х. Луннбек А/С	Похідні (3-алкоксіізоксазол-4-іл)заміщеної 2-амінокарбонової кислоти та їх сірковмісні аналоги, фармацевтична композиція на їх основі
US5990307A (en) *	1997-08-01	1999-11-23	American Home Products Corporation	Process for the preparation of [2-((8.9)-Dioxo-2,6-Diazabicyclo [5.2.0]-Non-1(7)-en-2yl) Ethyl]Phosphonic acid
KR100606580B1 (ko)	1997-08-01	2006-08-01	와이어쓰	[2-((8,9)-디옥소-2,6-디아자비사이클로[5.2.0]-논-1(7)-엔-2-일)에틸]포스폰산의 제조방법
US6541669B1 (en)	1998-06-08	2003-04-01	Theravance, Inc.	β2-adrenergic receptor agonists
US6225343B1 (en) *	1999-06-16	2001-05-01	Nastech Pharmaceutical Company, Inc.	Compositions and methods comprising morphine gluconate
UA78529C2 (en) *	2001-10-10	2007-04-10	Wyeth Corp	Derivatives of [[2-(amino-3,4-dioxo-1-cyclobutene-1-yl)amino]alkyl] acid for treating pain
US20040082543A1 (en)	2002-10-29	2004-04-29	Pharmacia Corporation	Compositions of cyclooxygenase-2 selective inhibitors and NMDA receptor antagonists for the treatment or prevention of neuropathic pain
BRPI0409088A (pt) *	2003-04-09	2006-04-11	Wyeth Corp	composições farmacêuticas para administração intranasal de ácido [2-(8,9-dioxo-2,6-diazabiciclo [5.2.0]non-1(7)-en-2-il)alquil]-fosfÈnico e derivados e métodos de uso dos mesmos
US6933289B2 (en)	2003-07-01	2005-08-23	Allergan, Inc.	Inhibition of irritating side effects associated with use of a topical ophthalmic medication
US20050142192A1 (en) *	2003-10-15	2005-06-30	Wyeth	Oral administration of [2-(8,9-dioxo-2,6-diazabicyclo[5.2.0]non-1(7)-en-2-yl)alkyl] phosphonic acid and derivatives

2004
- 2004-04-07 PT PT04759168T patent/PT1611144E/pt unknown
- 2004-04-07 CA CA002521313A patent/CA2521313A1/en not_active Abandoned
- 2004-04-07 WO PCT/US2004/010596 patent/WO2004092189A1/en not_active Ceased
- 2004-04-07 DK DK04759168.0T patent/DK1611144T3/da active
- 2004-04-07 AU AU2004230895A patent/AU2004230895B2/en not_active Ceased
- 2004-04-07 BR BRPI0409255-4A patent/BRPI0409255A/pt not_active IP Right Cessation
- 2004-04-07 ES ES04759168T patent/ES2350449T3/es not_active Expired - Lifetime
- 2004-04-07 MX MXPA05010760A patent/MXPA05010760A/es active IP Right Grant
- 2004-04-07 EP EP04759168A patent/EP1611144B1/en not_active Expired - Lifetime
- 2004-04-07 CN CN200480009542XA patent/CN1863810B/zh not_active Expired - Fee Related
- 2004-04-07 DE DE602004029146T patent/DE602004029146D1/de not_active Expired - Lifetime
- 2004-04-07 US US10/820,216 patent/US7253153B2/en not_active Expired - Fee Related
- 2004-04-07 AR ARP040101199A patent/AR044013A1/es not_active Application Discontinuation
- 2004-04-07 PL PL04759168T patent/PL1611144T3/pl unknown
- 2004-04-07 JP JP2006509747A patent/JP4621659B2/ja not_active Expired - Fee Related
- 2004-04-07 AT AT04759168T patent/ATE481103T1/de active
- 2004-04-08 CL CL200400769A patent/CL2004000769A1/es unknown
- 2004-04-08 TW TW093109670A patent/TWI349674B/zh not_active IP Right Cessation
2007
- 2007-06-01 US US11/757,006 patent/US7879825B2/en not_active Expired - Fee Related
2010
- 2010-10-25 CY CY20101100967T patent/CY1110863T1/el unknown

Also Published As

Publication number	Publication date
MXPA05010760A (es)	2005-12-12
JP4621659B2 (ja)	2011-01-26
WO2004092189A1 (en)	2004-10-28
US20070225257A1 (en)	2007-09-27
ES2350449T3 (es)	2011-01-24
AU2004230895B2 (en)	2010-09-09
DE602004029146D1 (de)	2010-10-28
EP1611144A1 (en)	2006-01-04
PT1611144E (pt)	2010-11-12
CA2521313A1 (en)	2004-10-28
US20050004080A1 (en)	2005-01-06
ATE481103T1 (de)	2010-10-15
AU2004230895A1 (en)	2004-10-28
US7879825B2 (en)	2011-02-01
CN1863810A (zh)	2006-11-15
US7253153B2 (en)	2007-08-07
CY1110863T1 (el)	2015-06-10
CL2004000769A1 (es)	2005-02-04
DK1611144T3 (da)	2010-11-22
TWI349674B (en)	2011-10-01
EP1611144B1 (en)	2010-09-15
TW200504085A (en)	2005-02-01
AR044013A1 (es)	2005-08-24
BRPI0409255A (pt)	2006-03-28
CN1863810B (zh)	2010-12-01
JP2006523694A (ja)	2006-10-19

Publication	Publication Date	Title
TWI349674B (en)	2011-10-01	Derivatives of [2-(8,9-dioxo-2,6-diazabicyclo[5.2.0]non-1(7)-en-2-yl)alkyl]phosphonic acid and methods of use thereof
HRP20090281T1 (hr)	2009-06-30	1,2,3,4-tetrasubstituirani indol za liječenje respiratornih bolesti
AP1614A (en)	2006-05-21	New heterocyclic compounds, their preparation and their use as medicaments, in particular as anti-bacterial agents.
PT911333E (pt)	2002-08-30	Derivados de pirazolo¬4,3-d\|pirimidina e composicoes farmaceuticas que os contenham
WO2002098856A3 (en)	2004-03-04	Piperazine oxyquinoline (naphthaline) platelet adenosine diphosphate receptor antagonists
MXPA04003534A (es)	2004-07-22	Derivados de lactam como antagonistas para receptores 11cby humanos.
MXPA05009508A (es)	2005-12-14	Derivados de nicotinamida 6-substituida como antagonistas de receptor opioide.
DE502004011328D1 (de)	2010-08-12	Substituierte hexahydro-pyrazino(1,2-a)pyrimidin-4,7-dionderivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
WO2004100865A3 (en)	2005-01-20	New benzimidazole derivatives
WO2002048148A3 (en)	2003-05-01	Pyrazolopyridine derivatives
WO2003051274A3 (en)	2003-10-30	Benzodiazepine derivatives, preparation thereof and use thereof
WO2005033066A3 (fr)	2006-05-11	Derives d'arylalkylcarbamates, leur preparation et leur application en therapeutique sanofi-synthelabo
CA2489140A1 (en)	2004-11-18	Dosage form containing pantoprazole as active ingredient
PL373624A1 (pl)	2005-09-05	Pochodne kwasu 4-(7-fluorowco-2-chino(ksa)linylooksy)-fenoksy propionowego jako środki przeciwnowotworowe
WO2004067703A3 (en)	2004-11-04	5ht7 antagonists and inverse agonists
MX2007000240A (es)	2007-06-15	Derivados de [1.2]-oxazin-3,5-diona y dihidropirona sustituidos con fenilo.
IL195837A0 (en)	2009-09-01	4-amino-3-arylamino-6-arylpyrazolo[3,4-d]
DK0896822T3 (da)	2003-06-02	4-aminopyrrol (3,2-d) pyrimidiner som neuropeptide Y receptorantagonister
SI1611144T1 (sl)	2010-12-31	Derivati 2-(8,9-diokso-2,6-diazabiciklo(5.2.0)non-1(7)-en-2-il)alkil fosfonske kisline in njihova uporaba kot antagonisti N-metil-D-aspartat(NMDA) receptorja
IL173445A (en)	2010-12-30	6-(1,1-difluoroalkyl)-4-aminopicolinates for use as herbicides
WO2004048381A3 (en)	2004-08-05	Pyrazoloazepine compounds as pharmaceutical agents
AU2001244999A1 (en)	2001-10-23	Naphthamide neurokinin antagonists for use as medicaments
GEP20063758B (en)	2006-02-27	Benzothia(Dia)Zine Derivatives and Method for Their Use as AMPA Modulators
ZA200603035B (en)	2009-09-30	Oral administration of [2-(8,9-dioxo-2,6-diazabicyclo[5.2.0.] non-1 (7)-en-2-yl)alkyl]phosphonic acid and derivatives
ZA200603236B (en)	2009-09-30	Methods for the preparation of {2-[8,9-dioxo-2,6-diaza-bicyclo[5.2.0]-non-1(7)-en-2-yl]ethyl} phosphonic acid and esters thereof